Sat.Apr 02, 2022 - Fri.Apr 08, 2022

Regeneron, in search of an eye gene therapy, turns to a young biotech

Bio Pharma Dive

Facing mounting competition to its top-selling drug Eylea, Regeneron is teaming up with ViGeneron to develop a genetic medicine for an inherited retinal disease

Three biggest threats to healthcare

World of DTC Marketing

Right now, voters are worried about inflation and rising fuel prices, but they ignore the imminent threats to their healthcare. American healthcare continues to be under assault, and unless we address these issues, a severe health issue could bankrupt families. THREAT 1: OBESITY AND DIABETES.


Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

The value of method of use patent claims in protecting your therapeutic assets

Drug Patent Watch

This is a guest post by Ray Miller and Megan E. Bowers, Ph.D. at DLA Piper. Ray may be contacted at When it comes to protecting therapeutic assets, I….

Drugs 93

Crowning a quest into a very well-guarded secret: Structure of the kinetochore corona finally revealed


Cell division builds our bodies, supplying all cells in our tissues and organs, from the skin to the intestine, from the blood to the brain. It not only allows these organs to grow, but also to regenerate with fresh cells when required.


2022 Research: The Rapid Rise of Ocean Freight Visibility

Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.

Medicare finalizes policy limiting coverage of Biogen Alzheimer's drug

Bio Pharma Dive

Treatment with Aduhelm would only be covered for patients enrolled in a clinical trial under the policy, which largely follows a draft proposal released in January

About those online metrics

World of DTC Marketing

It’s time to stop using worthless online ad metrics. Click-through rates are the most used KPI in marketing, but they are useless. Click-through rates don’t correlate with any meaningful brand metrics. Billions of dollars are “optimized” based on nothing but noise.

More Trending

Double-stranded RNA induces bone loss during gum disease


Tokyo University of Agriculture and Technology researchers reported on a new discovery regarding the mechanisms for bone loss in gum disease (periodontitis). They found that double stranded RNA molecules can activate the immune system response that leads to deterioration of bone.

RNA 87

Top Novartis executives to depart as company restructures

Bio Pharma Dive

The Swiss pharma said its plan to merge multiple business units and cut yearly costs by $1 billion is likely to impact jobs, but declined to specify which roles and how many


The four biggest challenges facing DTC marketers

World of DTC Marketing

DTC marketing has evolved. Those DTC managers who use the exact roadmap will waste a lot of money when accountability is increasing. Challenges await, and there isn’t one set of guidelines for every product category. Challenge #1 – DIGITAL MARKETING.

Upskilling in a digital health world

Pharma Phorum

It’s no secret that digital technologies are playing a significant role when it comes to shaping the next era of healthcare.

An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space

Speaker: Steve Goldstein, Sales Leader

Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.

CRISPR gene editing reveals biological mechanism behind common blood disorder


UNSW researchers have used CRISPR gene editing – a type of ‘molecular scissors’ – to understand how deletions in one area of the genome can affect the expression of nearby genes.

Akebia to lay off 42% of workforce, suspend trials after FDA drug rejection

Bio Pharma Dive

The layoffs come after safety concerns led the FDA to rebuff its anemia pill, similar to the agency's spurning of FibroGen's rival drug last year

Trials 242

Product launch metrics are changing in pharma

World of DTC Marketing

The old model of looking at performance in the first six months of product launch isn’t relevant. Today, colossal budget product launches are not returning the same ROI as before. Product launches are going to need to be micro-targeted to specific audiences.

Game-based therapies and the attraction of engaging patients

Pharma Phorum

Ensuring that patients remain consistent with their therapies is one of the major challenges facing healthcare, so what if you could make treatment a game? That’s the potential behind game-based digital therapeutics and it’s drawing a lot of interest, finds Ben Hargreaves.

Mandatory COVID Vaccination Policy Template

The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.

Study shows important change in B-cells in women with PPD


CHAPEL HILL, NC – A study published in Molecular Psychiatry is the first to look at multiple levels of biology within women with postpartum depression (PPD) to see how women with the condition differ from those without it.


FDA clears second Novartis plant for gene therapy manufacturing

Bio Pharma Dive

The 170,000-square-foot plant located in North Carolina can now fulfill its primary function: producing commercial-grade Zolgensma, which has become one of the Swiss pharma's top-selling drugs

Catalent buys UK vaccine manufacturing centre

BioPharma Reporter

US company Catalent is acquiring the UKâs Vaccine Manufacturing and Innovation Centre in Harwell: a facility which had been planned to support COVID-19 and wider vaccine production and which is still under construction. Upstream Processing

NIH funds study to evaluate long-term COVID in children

Pharma Phorum

The National Institutes of Health (NIH) is funding a nationwide study in the US to support research on long-COVID, chronic COVID, or as it’s scientifically known, post-acute sequelae of SARS-CoV-2 (PASC) in children.

Study finds US insiders to China news sold stock in early stages of pandemic


A new study of stock sales by U.S. executives with corporate ties to China indicates that corporate insiders sold stock in their companies during the earliest stages of the coronavirus outbreak in China, weeks before the virus spread to other countries and was recognized as a pandemic.

Sales 83

CAR-T treatment moves earlier as FDA widens approval of Gilead's Yescarta

Bio Pharma Dive

Yescarta, previously cleared only for use in treating late-stage lymphoma, can now be used after initial treatment has failed, a first for the cellular drugs

Drugs 229

Milestone approval for Kite CAR-T cell therapy

BioPharma Reporter

The US FDA has approved Yescarta, Kite's CAR-T cell therapy, for initial treatment in adults with large B-cell lymphoma (LBCL) that is refractory to one prior therapy or that relapses within 12 months of first-line chemoimmunotherapy. Markets & Regulations

Jazz adds first immuno-oncology drug via $1.3bn Werewolf deal

Pharma Phorum

Jazz Pharma has bolstered its pipeline of cancer drugs through a $1.3 billion licensing agreement with Werewolf Therapeutics that adds its first immuno-oncology candidate.

First integrated laser on lithium niobate chip


For all the recent advances in integrated lithium niobate photonic circuits — from frequency combs to frequency converters and modulators — one big component has remained frustratingly difficult to integrate: lasers.

A new approach for post-marketing safety studies

Bio Pharma Dive

The large quantity of digitized healthcare data in the U.S. presents an enormous opportunity to shift dramatically how post-marketing safety studies can and should be conducted

Abbott’s New Leadless Pacemaker Receives FDA Approval for Slow Heart Rhythms


The new single-chamber (VR) leadless pacemaker system by Abbott has a unique mapping capability that decreases the number of repositioning attempts needed. Every year, more than one million cardiac pacemakers are implanted worldwide, and over 200,000 of these occur in the US.

Digital health financing bonanza slows in Q1

Pharma Phorum

2021 was a big year in investment financing for US digital health companies, but there are signs that it may be a high watermark.

Air pollution responsible for 180,000 excess deaths in tropical cities


The international team of scientists aimed to address data gaps in air quality for 46* future megacities in Africa, Asia and the Middle East using space-based observations from instruments onboard NASA and European Space Agency (ESA) satellites for 2005 to 2018.

Viral vector design for gene therapies

Bio Pharma Dive

Safety issues in clinical trials cast doubt on the ability of gene therapy to safely mitigate disease, prompting further research into understanding the virus-host interaction that resulted in new generations of viral vectors

Personalized Blood Test Detecting ctDNA Can Help Predict Lung Cancer Relapse


The personalized ctDNA blood test uses the RaDaR™ assay, a liquid biopsy platform developed by the company Inivata. Photo source: Inivata.

DNA 85

Intouchers Spend Afternoon in Service to Displaced Ukrainians

Intouch Solutions

Philanthropy at Intouch has always been a big deal.

How T cell-derived interleukin-22 promotes antibacterial defense of colonic crypts


BIRMINGHAM, Ala. Intestinal epithelial cells line the inner wall of the gut, creating a barrier to dangerous bacteria like enteropathogenic E. coli that seek to attach and efface that barrier, causing diarrhea.

Pfizer buys a private biotech and its RSV drug research

Bio Pharma Dive

The pharma company adds experimental RSV treatments to its pipeline through the deal, which is worth up to $525 million

Lumen Bioscience: Spirulina-based platform enables rapid, low-cost development of oral biologics

BioPharma Reporter

Spirulina has been converted into a biomanufacturing platform that offers a way to rapidly produce mass quantities of biologic drugs for common diseases that currently lack effective treatments. Bio Developments

Drugs 83

Merck turns to cardiovascular pipeline for its post-Keytruda future

Pharma Phorum

For some years industry observers have been asking what Merck & Co can do to reduce its reliance on blockbuster cancer immunotherapy Keytruda. Now, it seems a key part of that effort will come from its cardiovascular disease pipeline.